

## Referências

Alix-Panabières C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. *Cancer discovery* 2016; May:479.

Cancer Genome Atlas. Genomic classification of cutaneous melanoma. *Cell*. 2015; 161:1681.

Chang MC, Chang YT, Chen JY, Jeng YM, Yang CY, Tien YW, Yang SH, Chen HL, Liang TY, Wang CF, Lee EY, Chang YC, Lee WH. Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma. *Clin Chem*. 2016; 62:505.

Chinen LT, de Carvalho FM, Rocha BM, Aguiar CM, Abdallah EA, Campanha D, Mingues NB, de Oliveira TB, Maciel MS, Cervantes GM, Dettino AL, Soares FA, Paterlini-Bréchet P, Fanelli MF. Cytokeratin-based CTC counting unrelated to clinical follow up. *J Thorac Dis*. 2013; 5:593.

Gray ES, Reid AL, Bowyer S, Calapre K, Pearce R, Cowell L, Frank MH, Millward M, Ziman M. Circulating melanoma cell subpopulations: their heterogeneity and differential responses to treatment. *J. Invest. Dermatol*. 2015; 135:2040e2048.

Khattak MA, Gray E, Freeman J, Pereira M, Meniawy T, Siew K, Millward M, Ziman M. PD-L1 expression on Circulating Melanoma Cells is predictive of response to Pembrolizumab. *Pigment Cell Melanoma Res*. 2017; 30:101.

Klein CA. Parallel progression of primary tumours and metastases. *Nat Rev Cancer* 2009;9:302.

Klinac D, Gray ES, Freeman JB, Reid A, Bowyer S, Millward M, Ziman M. Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. *BMC Canc*. 2014; 14: 423.

Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, Ranson M, Blackhall FH, Dive C. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. *J Thorac Oncol*. 2012; 7:306.

Reid AL, Millward M, Pearce R, Lee M, Frank MH, Ireland A, Monshizadeh L, Rai T, Heenan P, Medic S, Kumarasinghe P, Ziman M. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. *Br. J. Dermatol*. 2013; 168: 85e92.

Smith B, Selby P, Southgate J et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. *Lancet* 1991; 338: 1227.